adenine has been researched along with Koch's Disease in 12 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Comprehensive information on the effects of cytochrome P450 2B6 (CYP2B6) polymorphisms, clinical factors, and drug-drug interactions on efavirenz concentrations in HIV/tuberculosis-coinfected (HIV/TB) patients is unavailable." | 7.79 | Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. ( Lueangniyomkul, A; Mankatitham, W; Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S, 2013) |
| " Using a computer-generated randomisation sequence, we randomly allocated antiretroviral-naive adult patients with HIV-1 and tuberculosis (aged ≥18 years with a plasma HIV RNA concentration of >1000 copies per mL) to receive raltegravir 400 mg twice a day, raltegravir 800 mg twice daily, or efavirenz 600 mg once daily plus tenofovir and lamivudine (1:1:1; stratified by country)." | 5.19 | Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. ( Arnold, V; Barcellos, NT; Brites, C; Chêne, G; De Castro, N; Delaugerre, C; Fagard, C; Grinsztejn, B; Madruga, JV; Molina, JM; Morgado, M; Patey, O; Pilotto, JH; Santini-Oliveira, M; Santos, BR; Veloso, VG; Vorsatz, C, 2014) |
| "Comprehensive information on the effects of cytochrome P450 2B6 (CYP2B6) polymorphisms, clinical factors, and drug-drug interactions on efavirenz concentrations in HIV/tuberculosis-coinfected (HIV/TB) patients is unavailable." | 3.79 | Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. ( Lueangniyomkul, A; Mankatitham, W; Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S, 2013) |
| "We report on a Subsaharian patient with HIV infection and disseminated tuberculosis who developed acute, severe hypersensitivity reaction to efavirenz including acute renal failure in addition to liver and lung involvement, in the absence of skin changes or blood eosinophilia." | 3.73 | Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure. ( Angel-Moreno-Maroto, A; Hernández-Cabrera, M; Pérez-Arellano, JL; Suárez-Castellano, L, 2006) |
| " However, there is little data regarding the impact of this drug-drug Interaction in PLWH, which makes health care providers reluctant to prescribe them together." | 1.91 | The clinical impact of rifampicin-based anti-TB therapy and tenofovir alafenamide-containing ARV regimen drug Interaction in people living with HIV: Case series report. ( Alamer, A; Almulhim, A; Alrashed, A; Alwafai, S; Cahusac, P; Damfu, N; Mohzari, YA; Musawa, MA; Zaeri, B, 2023) |
| "This immune reconstitution inflammatory syndrome (TB-IRIS) can lead to significant morbidity and needs to be distinguished from TB recurrence due to ineffective treatment." | 1.40 | Biomarkers of CD4+ T-cell activation as risk factors for tuberculosis-associated immune reconstitution inflammatory syndrome. ( Boucherie, C; Breton, G; Bugault, F; Chakrabarti, LA; Chêne, G; Cumont, MC; Lortholary, O; Patey, O; Richert, L; Roussillon, C, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Naidoo, A | 1 |
| Dooley, KE | 1 |
| Naidoo, K | 1 |
| Padayatchi, N | 1 |
| Yende-Zuma, N | 1 |
| Perumal, R | 1 |
| Dorse, G | 1 |
| Boodhram, R | 1 |
| Osuala, EC | 1 |
| Mohzari, YA | 1 |
| Musawa, MA | 1 |
| Alrashed, A | 1 |
| Zaeri, B | 1 |
| Damfu, N | 1 |
| Cahusac, P | 1 |
| Alwafai, S | 1 |
| Alamer, A | 1 |
| Almulhim, A | 1 |
| Hu, Y | 1 |
| Wen, Z | 1 |
| Liu, S | 1 |
| Cai, Y | 1 |
| Guo, J | 1 |
| Xu, Y | 1 |
| Lin, D | 1 |
| Zhu, J | 1 |
| Li, D | 1 |
| Chen, X | 1 |
| Grinsztejn, B | 1 |
| De Castro, N | 1 |
| Arnold, V | 1 |
| Veloso, VG | 1 |
| Morgado, M | 1 |
| Pilotto, JH | 1 |
| Brites, C | 1 |
| Madruga, JV | 1 |
| Barcellos, NT | 1 |
| Santos, BR | 1 |
| Vorsatz, C | 1 |
| Fagard, C | 1 |
| Santini-Oliveira, M | 1 |
| Patey, O | 2 |
| Delaugerre, C | 1 |
| Chêne, G | 2 |
| Molina, JM | 1 |
| Chakrabarti, LA | 1 |
| Boucherie, C | 1 |
| Bugault, F | 1 |
| Cumont, MC | 1 |
| Roussillon, C | 1 |
| Breton, G | 1 |
| Richert, L | 1 |
| Lortholary, O | 1 |
| Hosseinipour, MC | 1 |
| Kumwenda, JJ | 1 |
| Weigel, R | 1 |
| Brown, LB | 1 |
| Mzinganjira, D | 1 |
| Mhango, B | 1 |
| Eron, JJ | 1 |
| Phiri, S | 1 |
| van Oosterhout, JJ | 1 |
| Manosuthi, W | 1 |
| Sukasem, C | 1 |
| Lueangniyomkul, A | 1 |
| Mankatitham, W | 1 |
| Thongyen, S | 1 |
| Nilkamhang, S | 1 |
| Manosuthi, S | 1 |
| Sungkanuparph, S | 1 |
| BEKIERKUNST, A | 2 |
| ARTMAN, M | 2 |
| SILMAN, N | 1 |
| ALEXANDER, N | 1 |
| Angel-Moreno-Maroto, A | 1 |
| Suárez-Castellano, L | 1 |
| Hernández-Cabrera, M | 1 |
| Pérez-Arellano, JL | 1 |
| Shen, Y | 1 |
| Shen, L | 1 |
| Sehgal, P | 1 |
| Zhou, D | 1 |
| Simon, M | 1 |
| Miller, M | 1 |
| Enimi, EA | 1 |
| Henckler, B | 1 |
| Chalifoux, L | 1 |
| Sehgal, N | 1 |
| Gastron, M | 1 |
| Letvin, NL | 1 |
| Chen, ZW | 1 |
| Tsukamura, M | 1 |
| Tsukamura, S | 1 |
| Mizuno, S | 1 |
| Toyama, H | 1 |
| Okada, K | 1 |
| Oshima, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2b Study to Evaluate the Efficacy, Safety and PK of a Combination of Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate for Treatment of HIV-1 Infection in Patients With Drug-susceptible Tuberculosis on a Rifampicin-based Regimen[NCT04734652] | Phase 2 | 120 participants (Anticipated) | Interventional | 2022-02-18 | Recruiting | ||
| Phase II Open-label Randomized Multicenter Trial to Compare the Efficacy and Safety of Two Different Doses of Raltegravir and Efavirenz, All in Combination With Tenofovir and Lamivudine, in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuber[NCT00822315] | Phase 2 | 155 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for adenine and Koch's Disease
| Article | Year |
|---|---|
INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection i
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Fumarates; Heterocyclic Compounds, | 2022 |
Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agen | 2014 |
10 other studies available for adenine and Koch's Disease
| Article | Year |
|---|---|
The clinical impact of rifampicin-based anti-TB therapy and tenofovir alafenamide-containing ARV regimen drug Interaction in people living with HIV: Case series report.
Topics: Adenine; Adolescent; Anti-HIV Agents; Anti-Retroviral Agents; Drug Interactions; Female; HIV Infecti | 2023 |
Ibrutinib suppresses intracellular mycobacterium tuberculosis growth by inducing macrophage autophagy.
Topics: Adenine; Animals; Autophagy; Macrophages; Mice; Mycobacterium tuberculosis; Piperidines; Tuberculosi | 2020 |
Biomarkers of CD4+ T-cell activation as risk factors for tuberculosis-associated immune reconstitution inflammatory syndrome.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; CD4-Positive T-Lymphocytes; Cycl | 2014 |
Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Body Mass Index; CD4 Lymphocyte Count; Developin | 2010 |
Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydrox | 2013 |
TISSUE METABOLISM IN INFECTION. SOLUBLE NICOTINAMIDE-ADENINE DINUCLEOTIDASE IN ORGANS FROM TUBERCULOUS MICE.
Topics: Adenine; Animals; Liver; Lung; Metabolism; Mice; Mycobacterium tuberculosis; NAD; Niacin; Niacinamid | 1964 |
NICOTINAMIDE ADENINE DINUCLEOTIDASE ACTIVITY IN CELLS OF TUBERCULOUS ANIMALS.
Topics: Adenine; Animals; Guinea Pigs; Leukocytes; Lymphoid Tissue; Metabolism; Mice; Monocytes; NAD; Niacin | 1964 |
Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure.
Topics: Acute Kidney Injury; Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Hyp | 2006 |
Antiretroviral agents restore Mycobacterium-specific T-cell immune responses and facilitate controlling a fatal tuberculosis-like disease in Macaques coinfected with simian immunodeficiency virus and Mycobacterium bovis BCG.
Topics: Adenine; Animals; Antiviral Agents; Cells, Cultured; HIV Protease Inhibitors; Indinavir; Macaca mula | 2001 |
Effect of adenine on tuberculous infection and BCG vaccination in mice.
Topics: Adenine; Animals; BCG Vaccine; Culture Media; Mice; Tuberculosis | 1966 |